News|Articles|March 30, 2026
Q2 2026 preview: 4 FDA decisions to watch in pediatric care
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Yasmeen Qahwash
A review of 4 drugs to be discussed by the US FDA during Q2 2026, with links to coverage from MJH Life Sciences publications.
Advertisement
Advertisement
The second quarter of 2026 will include multiple advancements in pediatric care, including 4 drugs to be discussed by the FDA that will significantly advance disease management in this population. These include inhaled insulin (Afrezza), a rapid-acting inhaled human insulin for glycemic control, and teplizumab (Tzield), a disease-modifying intervention to delay the onset of type 1 diabetes.
Advertisement
Advertisement